Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MicroMTx002
- Development stage
- Preclinical
- Lead developer
- MicroCrispr
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MicroMTx002 is a preclinical universal mRNA therapeutic candidate being developed by MicroCrispr for the treatment of various solid tumors. The program targets a broad range of indications, including lung, pancreatic, colorectal, skin, head and neck, and prostate cancers. As a universal mRNA therapeutic, the candidate is designed to leverage mRNA technology to deliver therapeutic instructions to cells, although the specific molecular targets, payloads, and delivery mechanisms have not been publicly detailed by the company. The drug is currently in the preclinical stage of development and is part of the company's living therapeutics portfolio.
Beyond the preview
Go deeper on MicroMTx002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroMTx002.